Introduction to Xenograft Models
Xenograft models represent a cornerstone of modern oncology, immunology, and therapeutic development. These models involve the implantation of human-derived cells or tissues into immunodeficient rodents to study human disease progression, drug response, and molecular pathways in a living organism. Among various xenograft host models, the NOD/SCID (Non-Obese Diabetic/Severe Combined Immunodeficient) mouse has emerged as a premier platform due to its profound immunosuppression, enabling high-efficiency engraftment of human tumors, immune cells, and stem cells. This animal model facilitates studies of human cancer biology, immune escape mechanisms, drug efficacy, and resistance development in a physiological context closely mimicking human systems.
Immunodeficient Profile of NOD/SCID Mice
NOD/SCID mice are genetically engineered to lack functional T cells and B cells due to the SCID mutation, and exhibit impaired natural killer (NK) cell activity owing to the NOD background. The NOD mutation also contributes to deficiencies in macrophage and dendritic cell function, reduced complement system activity, and altered cytokine signaling. This immunological void enables efficient xenotransplantation of human hematopoietic stem cells, solid tumor cell lines, and primary patient-derived tumors without the risk of acute rejection. NOD/SCID mice lack adaptive immune surveillance and show compromised innate immune responses, making them an ideal host for long-term engraftment and serial passaging of human tissues. Despite partial NK activity remaining in these mice, it is significantly reduced compared to other strains such as BALB/c or athymic nude mice, offering a superior engraftment environment for sensitive or immunogenic human cells.
Tumor Engraftment and Study Design
Human tumor cell lines, patient-derived xenografts (PDX), or genetically modified human cells are introduced into NOD/SCID mice via subcutaneous, orthotopic, or intravenous routes, depending on the study objectives. Subcutaneous implantation allows for easy tumor volume monitoring using calipers, while orthotopic injections place the tumor within its native anatomical site, preserving microenvironmental cues and metastatic potential. For studies of hematologic malignancies or metastatic spread, intravenous or intracardiac administration is utilized, enabling disseminated tumor formation. Tumor latency, growth kinetics, angiogenesis, and response to treatment are recorded using caliper measurements, in vivo imaging systems (IVIS), and postmortem histopathological analyses. Treatment cohorts may be administered chemotherapeutic agents, small molecule inhibitors, RNA therapeutics, antibody-drug conjugates, or gene-editing reagents to evaluate efficacy, toxicity, and resistance.
Pharmacological Evaluation and Drug Testing
NOD/SCID mice are extensively used in preclinical pharmacology for the evaluation of novel oncology therapeutics. These models enable dose optimization, pharmacokinetics (PK), pharmacodynamics (PD), and toxicology studies within the context of a humanized tumor microenvironment. Test articles are delivered through clinically relevant routes such as intravenous, intraperitoneal, oral gavage, or subcutaneous injection. Tumor regression, growth inhibition, and time to progression are quantified alongside molecular biomarkers of efficacy. Tissue samples collected at defined timepoints allow for RNA, DNA, and protein analyses including qRT-PCR, Western blotting, ELISA, immunohistochemistry, and flow cytometry. Molecular endpoints such as apoptosis (cleaved caspase-3), cell proliferation (Ki-67), angiogenesis (CD31), and immune infiltration (CD45, CD8, CD4) are evaluated to gain mechanistic insights. For RNA-based therapies, knockdown efficiency is validated using digital PCR or transcriptome-wide sequencing. The model is also used to evaluate off-target effects, toxicity biomarkers, and therapeutic windows.
Applications in Immuno-oncology and Cell Therapy
Despite their immunodeficient status, NOD/SCID mice serve as a key model for evaluating adoptive cell therapies, including CAR-T and TCR-engineered T cells, when co-engrafted with human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells. While they do not support full immune reconstitution like NSG mice, their compatibility with partial immune engraftment permits evaluation of cell expansion, persistence, tumor targeting, and cytotoxicity in vivo. Moreover, NOD/SCID mice are used in studies of human immune tolerance, cytokine release, immune checkpoint blockade, and tumor immune evasion. These models enable screening of combination therapies involving checkpoint inhibitors (anti-PD-1, anti-CTLA-4) alongside novel agents targeting tumor-intrinsic or microenvironmental pathways.
Humanized Model Capabilities
To extend the utility of NOD/SCID mice in human immunology, researchers employ bone marrow-liver-thymus (BLT) reconstitution or CD34+ hematopoietic stem cell transplantation, enabling the development of functional human immune compartments within the murine host. This approach creates a “humanized mouse” that supports T cell development, antigen presentation, and immune effector function. These humanized NOD/SCID models are used in studies of infectious diseases, autoimmune mechanisms, immune-oncology interactions, and transplantation tolerance. The ability to model human tumor-immune dynamics in vivo accelerates the development of personalized therapies and supports mechanistic studies of tumor microenvironment modulation.
Tissue Analysis and Molecular Endpoints
Following study termination, tumors and organs are harvested for comprehensive analysis. Formalin-fixed, paraffin-embedded (FFPE) sections undergo H&E staining, immunohistochemical detection of target proteins, and in situ hybridization for gene expression localization. Cryopreserved tissues are processed for RNA isolation, protein extraction, and DNA genotyping. Tumor burden is quantified using image analysis software, and mitotic index, necrosis, and fibrosis are scored semi-quantitatively. Advanced omics technologies including transcriptomics, proteomics, and single-cell RNA sequencing are employed to profile tumor evolution, heterogeneity, and resistance mechanisms. Circulating biomarkers, such as tumor-derived exosomes, ctDNA, and circulating cytokines, can be evaluated longitudinally using serum collected at different timepoints.
Advantages and Limitations
The NOD/SCID model offers high engraftment efficiency, long-term xenograft persistence, and robust tumor growth kinetics with minimal host interference. It is suitable for a broad range of cancer types including hematologic malignancies (e.g., leukemia, lymphoma) and solid tumors (e.g., breast, colon, pancreas, lung, and brain). However, some limitations include residual NK activity, inability to support full immune reconstitution without additional genetic modifications, and susceptibility to thymic lymphomas or diabetes in aging animals. As such, experiments should be carefully timed and designed with appropriate controls to mitigate variability.
Altogen Labs: Xenograft Services Using NOD/SCID Mice
Altogen Labs provides customized xenograft model development and therapeutic testing services using immunocompromised NOD/SCID mice. Services include tumor cell line or PDX implantation, study design consultation, dosing regimen optimization, in-life monitoring, tumor growth evaluation, endpoint molecular analyses, and regulatory-grade reporting. With capabilities spanning traditional xenograft studies to advanced humanized models and nanoparticle-mediated delivery of RNA therapeutics, Altogen Labs supports a wide range of preclinical research initiatives. The use of validated protocols, GLP-compliant infrastructure, and experienced technical teams ensures high-quality, reproducible results for IND-enabling and mechanistic studies.